Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy

Background. Natalizumab is a highly effective treatment approved for multiple sclerosis (MS). The opening of the blood-brain barrier mediated by matrix metalloproteinases (MMPs) is considered a crucial step in MS pathogenesis. Our goal was to verify the utility of serum levels of active MMP-2 and MM...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Dis Markers
Main Authors: Castellazzi, Massimiliano, Bellini, Tiziana, Trentini, Alessandro, Delbue, Serena, Elia, Francesca, Gastaldi, Matteo, Franciotta, Diego, Bergamaschi, Roberto, Manfrinato, Maria Cristina, Volta, Carlo Alberto, Granieri, Enrico, Fainardi, Enrico
פורמט: Artigo
שפה:Inglês
יצא לאור: Hindawi Publishing Corporation 2016
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4909921/
https://ncbi.nlm.nih.gov/pubmed/27340316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/8434209
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים